Evidence map›Paper›PMID 40413163›Full record

ArticleNPJ breast cancer2025

Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis.

Celine Yeh, Rachel Han, Abha Kulkarni, Charlie White, Yuan Chen, Matthew G Hanna, Edi Brogi, Andrew D Seidman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Celine Yeh *Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY, USA.
Rachel Han *Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA.
Abha KulkarniWeill Cornell Medicine, Department of Medicine, New York, NY, USA.
Charlie WhiteMemorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
Yuan ChenMemorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
Matthew G HannaMemorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA.
Edi BrogiMemorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA.ORCID http://orcid.org/0000-0003-4737-8468
Andrew D SeidmanMemorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY, USA. seidmana@mskcc.org.ORCID http://orcid.org/0000-0002-5064-3966

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

We conducted a retrospective analysis of 213 patients with HER2+ T1micN0 breast cancer. Patients with ≥5 foci of microinvasion received more aggressive treatment with higher rates of sentinel lymph node biopsy and adjuvant chemotherapy/HER2-targeted therapy (CT/H2TT) than patients with 1-4 foci. We did not detect significant differences in invasive disease-free survival between patients with 1-4 and ≥5 foci, or between patients with ≥5 foci who did and did not receive adjuvant CT/H2TT.

Identifiers

PMID40413163
PMCPMC12103504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.